Interstitial lung disease (ILD) remains a significant complication of rheumatoid arthritis (RA), impacting patient quality of life and increasing mortality risk. A multidisciplinary panel of experts has developed consensus recommendations to standardize care for RA-ILD, focusing on identifying at-risk patients, enhancing screening strategies, and guiding treatment decisions.
Factors increasing the risk of RA-ILD include older age, male sex, smoking history, and seropositive rheumatoid arthritis. Recognizing these traits allows for enhanced respiratory monitoring and timely investigations. The panel advocates for proactive screening, utilizing clinical assessments, pulmonary function tests, and high-resolution CT scans to facilitate early intervention.
Treatment approaches should be tailored based on disease severity, symptoms, and patient preferences. The consensus underscores the collaborative role of healthcare specialists in optimizing patient outcomes, particularly regarding the use of immunomodulatory and antifibrotic therapies. Further research is essential, yet the recommendations aim to improve outcomes for patients and address the complexities of managing RA-ILD.